Xylometazoline
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
- Xylometazoline
- Pharmacist Assessment Report
- Xylometazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Xylometazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
One-Sentence Summary
Xylometazoline is a topical nasal decongestant, originally used for the common cold and pharyngitis. The TxGNN model predicts it may be effective for nasal cavity disease, with no registered clinical trials but 6 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis, common cold (the Canadian licence records contain no indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled records. Based on general pharmacology, xylometazoline is an imidazoline-derivative alpha-adrenergic agonist applied to the nose. It constricts the blood vessels of the nasal lining, which reduces swelling and nasal airway resistance. Pharmacology records list activity at alpha-2A, alpha-2B and alpha-2C adrenoceptors in humans, but no affinity data were found to confirm a primary target.
The original indications (common cold and pharyngitis) involve nasal congestion and swollen mucosa. “Nasal cavity disease” is a broader category covering the same problem, so the prediction is largely an extension of existing use rather than a completely new direction. The published studies support this, showing decongestant effects in nasal preparation for endoscopy and intubation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24158493 | 2013 | Randomized, double-blind, placebo-controlled trial | JAMA Otolaryngol Head Neck Surg | Topical anaesthetic plus decongestant spray before flexible nasendoscopy in children, compared with placebo |
| 22427029 | 2013 | Prospective randomized blinded study (100 patients) | Eur Arch Otorhinolaryngol | Cotton pledget packing compared with topical spray for nasal preparation before endoscopy |
| 24023995 | 2013 | Clinical study | Korean J Anesthesiol | Xylometazoline spray compared with epinephrine gauze packing for expanding the nasal cavity before nasotracheal intubation |
| 8740084 | 1996 | Double-blind randomized study (18 subjects) | Arzneimittel-Forschung | Tuaminoheptane plus N-acetylcysteine compared with xylometazoline and placebo for reducing nasal resistance; xylometazoline served as a comparator |
| 1281924 | 1992 | Physiological/clinical study | Rhinology | Nasal airflow asymmetry in healthy subjects and people with common-cold rhinitis, and how xylometazoline affected it |
| 34783482 | 2021 | Review | Vestnik Otorinolaringologii | Nasal mucosa changes in the elderly and treatment of inflammatory nasal and sinus disease, including combined decongestant sprays |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02208903 | Otrivin Medicated Cold & Allergy Relief with Moisturizers | Not listed | Not listed |
| 02452863 | Nasal Decongestant Spray with Moisturizers | Not listed | Not listed |
| 00653330 | Otrivin Medicated Cold & Allergy Relief | Not listed | Not listed |
| 02452812 | Decongestant Nasal Spray | Not listed | Not listed |
| 02331403 | Otrivin Medicated Complete Nasal Care | Not listed | Not listed |
All five licences are valid single-ingredient products. None are cancelled.
Safety Considerations
- Disease-based cautions (from the knowledge graph, not label text): Contraindication links were found for hypertension and other hypertensive disorders, heart and cardiovascular disease, diabetes mellitus and diabetic ketoacidosis, and hyperthyroidism (including Graves disease and thyrotoxicosis).
- Drug Interactions: The interaction search returned 5 records. These are pharmacology target associations (alpha-1D, alpha-2A, alpha-2B and alpha-2C adrenoceptors, and TAAR4P), not drug-drug interactions with severity ratings. Caution is also advised with MAO inhibitors, based on general pharmacology.
- Duration of use: Use should generally be limited to under 7 days because of the risk of rebound congestion (rhinitis medicamentosa).
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism is consistent with its marketed use, and several clinical studies, including one randomized placebo-controlled trial, show decongestant effects in nasal procedures. However, there are no registered trials for this indication, and most studies are small or use xylometazoline as a comparator or part of a combination. The prediction also largely overlaps with existing use.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data, such as from DrugBank
- Approved indication text and dosage forms for the Canadian licences
- Clear definition of the target conditions within “nasal cavity disease”
- A plan limiting duration of use and screening patients with cardiovascular disease, hypertension, diabetes or thyroid disease, and those taking MAO inhibitors
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.